GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

Abroad (travel likely)RecruitingPHASE2

Conditions

Intrahepatic Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Contact: Study coordinator (Yuhua - Zhang, M.D.) · drzhangyuhua@126.com · +86-0571-88128058
Contact: Study coordinator (Jia - Wu) · tkds123@qq.com · +86-0571-88128052
Jia Wu, Hanzhou, Zhejiang, China
Contact: Study coordinator (Jia Wu) · tkds123@qq.com · 086-0571-88128058

Study leads

Yuhua - Zhang, M.D.
Study Chair
Zhejiang Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Irvine, United States · Los Angeles, United States

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Fairfax, United States

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China